PT2242740E - Derivados de sf5 como inibidores do par1, sua preparação e utilização como produtos farmacêuticos - Google Patents

Derivados de sf5 como inibidores do par1, sua preparação e utilização como produtos farmacêuticos

Info

Publication number
PT2242740E
PT2242740E PT97090898T PT09709089T PT2242740E PT 2242740 E PT2242740 E PT 2242740E PT 97090898 T PT97090898 T PT 97090898T PT 09709089 T PT09709089 T PT 09709089T PT 2242740 E PT2242740 E PT 2242740E
Authority
PT
Portugal
Prior art keywords
medicaments
derivatives
production
par1 inhibitors
par1
Prior art date
Application number
PT97090898T
Other languages
English (en)
Inventor
Karl Schoenafinger
Uwe Heinelt
Volkmar Wehner
Matthias Hermann
Henning Steinhagen
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PT2242740E publication Critical patent/PT2242740E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
PT97090898T 2008-02-05 2009-01-23 Derivados de sf5 como inibidores do par1, sua preparação e utilização como produtos farmacêuticos PT2242740E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290115 2008-02-05

Publications (1)

Publication Number Publication Date
PT2242740E true PT2242740E (pt) 2013-02-06

Family

ID=39322588

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97090898T PT2242740E (pt) 2008-02-05 2009-01-23 Derivados de sf5 como inibidores do par1, sua preparação e utilização como produtos farmacêuticos

Country Status (10)

Country Link
US (1) US8466169B2 (pt)
EP (1) EP2242740B1 (pt)
JP (1) JP2011511018A (pt)
CY (1) CY1113911T1 (pt)
DK (1) DK2242740T3 (pt)
ES (1) ES2400322T3 (pt)
HR (1) HRP20130160T1 (pt)
PT (1) PT2242740E (pt)
SI (1) SI2242740T1 (pt)
WO (1) WO2009097972A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010007893A (es) 2008-02-05 2010-08-09 Sanofi Aventis Sales de triazolio como inhibidores del par1, produccion de las mismas, y uso como medicamentos.
CN101981034B (zh) * 2008-02-05 2013-08-14 赛诺菲-安万特 作为par1抑制剂的三唑并哒嗪、其制备及其制备药物的用途
US8673890B2 (en) 2009-10-29 2014-03-18 Janssen Pharmaceutica Nv 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist
EP2335717A1 (en) * 2009-11-16 2011-06-22 Institut National De La Recherche Agronomique PAR-1 antagonists for use in the treatment or prevention of influenza virus type a infections
EP3527569B1 (en) 2014-02-03 2021-08-25 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma for use in treating drye eye
PT3207043T (pt) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
CN108463458B (zh) 2015-11-20 2022-02-01 生命医药有限责任公司 ROR-γ的调节剂
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
UA126583C2 (uk) 2017-07-24 2022-11-02 Вітае Фармасьютікалс, Ллс ІНГІБІТОРИ ROR<font face="Symbol">g</font>
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
WO2022017524A1 (zh) * 2020-07-23 2022-01-27 深圳晶泰科技有限公司 吡啶酮类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040242627A1 (en) * 2001-04-19 2004-12-02 Shuichi Suzuki 2-Iminoimidazole derivatives (1)
US6956046B2 (en) 2001-05-25 2005-10-18 Mochida Pharmaceutical Co., Ltd. 4-hydroxypiperidine derivatives having analgesic activity
EP1439178A4 (en) * 2001-10-05 2005-11-16 Takeda Pharmaceutical HETEROCYCLIC COMPOUNDS, OXAZOLE DERIVATIVES, PROCESS FOR THEIR PRESENTATION AND USE THEREOF
US6896942B2 (en) 2002-04-17 2005-05-24 W. R. Grace & Co. -Conn. Coating composition comprising colloidal silica and glossy ink jet recording sheets prepared therefrom
US7375138B2 (en) * 2002-05-18 2008-05-20 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them
EP1602646A4 (en) 2003-02-19 2010-07-28 Eisai R&D Man Co Ltd PROCESS FOR PREPARING CYCLIC BENZAMIDINE DERIVATIVES
DE10353205A1 (de) 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als wertvolle Synthese-Zwischenstufen
OA13285A (en) 2003-11-13 2007-01-31 Sanofi Aventis Deutschland Pentafluorosulfanyl benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing the same.
TW200531688A (en) * 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
WO2006018955A1 (ja) 2004-08-16 2006-02-23 Eisai R & D Management Co., Ltd. イソインドール誘導体の製造方法
US7956222B2 (en) 2004-08-17 2011-06-07 Eisai R&D Management Co., Ltd Methods for producing dibromofluorobenzene derivatives
WO2006051623A1 (ja) 2004-11-09 2006-05-18 Eisai Co., Ltd. トロンビン受容体アンタゴニストを有効成分とするくも膜下出血に伴う血管攣縮の治療剤

Also Published As

Publication number Publication date
DK2242740T3 (da) 2013-03-25
JP2011511018A (ja) 2011-04-07
US20110034461A1 (en) 2011-02-10
EP2242740B1 (de) 2012-12-12
US8466169B2 (en) 2013-06-18
SI2242740T1 (sl) 2013-03-29
WO2009097972A1 (de) 2009-08-13
EP2242740A1 (de) 2010-10-27
HRP20130160T1 (hr) 2013-03-31
ES2400322T3 (es) 2013-04-09
CY1113911T1 (el) 2016-07-27

Similar Documents

Publication Publication Date Title
SI2242740T1 (sl) SF5-derivati kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila
IL254076B (en) 5-Fluoropyrimidinone derivatives, preparations containing them and methods of using them
IL214175A (en) Derivatives of aminotetralin, their pharmaceutical compositions and their use
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
HK1162352A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
IL219646A0 (en) Novelnaphthyridine derivatives and the use thereof as kinase inhibitors
PL2307391T3 (pl) Tiadiazolilooksyfenyloamidyny i ich zastosowanie jako środki grzybobójcze
ZA201000185B (en) 17beta-cyano-18a-homo-19-nor-androst-4-ene derivative,use thereof and medicaments containing said derivative
IL204442A (en) Inhibitors of atpase-0fif, medicinal preparations containing them and their use
IL209421A (en) Kionoxalindone derivatives, medicines containing them and their use
EP2239261A4 (en) PYRROLOPYRIMIDINE DERIVATIVE FOR USE AS A PI3K INHIBITOR AND USE THEREOF
IL206394A (en) Derivatives of 2-Benzylpyridine Filtration as Met Kinase Inhibitors, Process for their Preparation, Medication and Use
IL195245A0 (en) Substituted prolinamides, production thereof and their use as drugs
IL206808A (en) Indolyl-pyridone history, their pharmaceutical preparations and their uses
PL2307390T3 (pl) Tiadiazolilooksyfenyloamidyny i ich zastosowanie jako środki grzybobójcze
IL216113A (en) Processed derivatives of indazole and azaza-indazole, pharmaceutical preparations containing them and their uses
HK1167597A1 (en) Dodeca-2e,4e-diene amides and their use as medicaments and cosmetics -2e4e-
IL211713A (en) History of Anilinopyrimidine Converted to Sulfoxaamine as CDK Inhibitors, Manufactured and Used as Drugs
IL209840A0 (en) Azacarboline derivatives, preparation thereof, and therapeutic use thereof as kinase inhibitors
ZA200908612B (en) 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
IL208771A0 (en) Iminopyridine derivatives and use thereof
HK1162494A1 (en) Sulfone-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as a medicine cdk
IL220586A (en) Carboxamide compound, a pharmaceutical composition containing it and its use
HK1149012A1 (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
HK1148956A1 (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments